Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature-Reference-Cited by-同舟云学术

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature

Published:2016-02 Issue:2 Volume:11 Page:174-186
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Zhou Caicun,Yao Luan Di

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference83 articles.

1. Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non–small-cell lung cancer: a 10-year retrospective population-based review;Ho;J Thorac Oncol,2014

2. American Cancer Society. Lung Cancer (Non–Small Cell). Available at http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-survival-rates. Updated March 4, 2015. Accessed May 19, 2015.

3. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

4. West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

5. North-East Japan Study Group. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Combination of Therapeutic Approaches in Advanced NSCLC with EGFR Activating Mutations;Targets;2024-09-07

2. Inhibiting G6PD by quercetin promotes degradation of EGFR T790M mutation;Cell Reports;2023-11

3. Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis;BMC Pulmonary Medicine;2023-06-14

4. First-, Second-, and Third-Generation Radiolabeled Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Positron Emission Tomography: State of the Art, a Systematic Review;Cancer Biotherapy and Radiopharmaceuticals;2023-05-01

5. Targeting potential receptor molecules in non-small cell lung cancer (NSCLC) using in silico approaches;Frontiers in Molecular Biosciences;2023-02-09